Why Is Theriva Biologics Stock Gaining Monday?

Benzinga_recent_news2025-12-30

Theriva Biologics, Inc. (NYSE:TOVX) stock rose on Monday, with a session volume of 114.18 million compared to the average volume of 15.61 million, as per data from Benzinga Pro. The company received ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595734835?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-30 00:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595734835","market":"us","top_or_hot":-1,"title":"Why Is Theriva Biologics Stock Gaining Monday?","media":"Benzinga_recent_news","content":"<div>\n<p>Theriva Biologics, Inc. (NYSE:TOVX) stock rose on Monday, with a session volume of 114.18 million compared to the average volume of 15.61 million, as per data from Benzinga Pro.\nThe company received ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Theriva Biologics Stock Gaining Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Theriva Biologics Stock Gaining Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-30 00:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Theriva Biologics, Inc. (NYSE:TOVX) stock rose on Monday, with a session volume of 114.18 million compared to the average volume of 15.61 million, as per data from Benzinga Pro.\nThe company received ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4087","symbol_name":"商业印刷","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday","article_id":"2595734835","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2595734835","pubTimestamp":1767026460,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4087":"商业印刷","LU2360107325.USD":"BGF FUTURE OF TRANSPORT \"A4\" (USD) INC","LU0124384867.USD":"贝莱德新能源基金A2","LU1861220033.SGD":"Blackrock Next Generation Technology A2 SGD-H","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","CHMP":"冠军工业","TOVX":"Theriva Biologics","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU1861215975.USD":"贝莱德新一代科技基金 A2","EMA":"Emera Inc.","BK4512":"苹果概念","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4141":"半导体产品","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","LU1861214812.USD":"Blackrock Future of Transport A2 USD","BK4605":"半导体精选","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","ON":"安森美半导体","BK4588":"碎股","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1861219969.SGD":"Blackrock Future of Transport A2 SGD-H","BK4081":"电力公用事业","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4215":"住宅房地产投资信托","MAA":"MAA房产信托","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc"},"translate_title":"为什么Theriva Biologics股票周一上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":1.5,"ON":0.63,"CHMP":1,"MAA":1,"EMA":1},"content_text":"Theriva Biologics, Inc. (NYSE:TOVX) stock rose on Monday, with a session volume of 114.18 million compared to the average volume of 15.61 million, as per data from Benzinga Pro.\nThe company received Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on the design of a Phase 3 trial of lead clinical candidate VCN-01.\nThe trial will evaluate VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).\nAlso Read: Analysts Raise Price Targets Following Strong Data From Revolution Medicines’ Pancreatic Cancer Drug\nThe company has previously reported the results of the VIRAGE phase 2 trial, demonstrating that PDAC patients in the VCN-01 plus gemcitabine/nab-paclitaxel SoC treatment arm demonstrated increased overall survival, progression-free survival, and duration of response compared to patients in the control arm treated with gemcitabine/nab-paclitaxel SoC alone.\nEven greater increases in these parameters were observed in patients who received two doses of VCN-01 administered 3 months apart.\nCHMP advised that a potential future marketing authorization application (MAA) for VCN-01 in metastatic PDAC could be supported by Theriva’s proposed clinical development strategy if the phase 3 trial demonstrates a compelling benefit-risk ratio with VCN-01 plus gemcitabine/nab-paclitaxel SoC compared to gemcitabine/nab-paclitaxel SoC alone.\nThe CHMP recognized the increased improvement in overall survival of patients receiving two doses of VCN-01 in the VIRAGE study, and agreed with the proposed dosing of VCN-01 and gemcitabine/nab-paclitaxel in repeated “macrocycles”, enabling more than two doses of VCN-01 to be administered in the Phase 3 trial.\nThey further suggested that more frequent dosing of VCN-01 could be considered.\nOn November 10, 2025, Theriva had $15.5 million in cash and equivalents, providing runway into the first quarter of 2027 as the company completes interactions with regulatory agencies regarding the PDAC and retinoblastoma programs and pursues partnerships to support VCN-01 manufacturing scale-up and conduct of the proposed pivotal clinical trial(s).\nTOVX Price Action: Theriva Biologics shares were up 4.03% at $0.19 at the time of publication on Monday, according to Benzinga Pro data.\nRead Next:\nImage via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595734835","isCrawlerRequest":true}